An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection.

You likely can't join if

• Participants who are known or suspected to be hypersensitive to any component of the study medication.
• Participants who, in the judgment of the investigator, are unlikely to complete the course of treatment due to their current disease process.
• Liver function: • Subjects who meet the following criteria at Baseline: ALT ≥3xULN with Bilirubin ≥2xULN or Isolated bilirubin ≥ 2xULN and >50% direct bilirubin or ALT ≥5xULN Inclusion of subjects with liver function tests that fall outside these criteria must be discussed and agreed with the medical monitor. • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of benign conditions such as Gilbert's syndrome). Inclusion of subjects with neonatal hyperbilirubinaemia may be considered if appropriately managed according to local guidelines and must be discussed with the medical monitor.
• Participants who require concurrent therapy with another anti influenza drug.
• Participants who have participated in a study using an investigational drug within 30 days prior to Baseline.
• Child in care (CiC), as defined below: • A child who has been placed under the control or protection of an agency, organisation, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. • The definition of a CiC can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a CiC does not include a child who is adopted or has an appointed legal guardian.